From the Division of Plastic Surgery, Baylor College of Medicine; and the Department of Plastic Surgery, Kelsey Seybold Clinic.
Plast Reconstr Surg. 2020 Feb;145(2):240e-250e. doi: 10.1097/PRS.0000000000006501.
Periprosthetic infections represent major complications in breast reconstruction, frequently leading to expander-implant loss. No consensus regarding a management algorithm for attempted salvage currently exists. This study assessed outcomes of the authors' salvage protocol using an antibiotic-impregnated polymethylmethacrylate implant with expander device exchange.
A retrospective chart review identified infected implant-based breast reconstruction cases treated between 2009 and 2017. Of 626 cases initially identified, a total of 62 cases had severe prosthetic infections, and underwent either prosthetic salvage (n = 45) or immediate explantation (n = 17). All the prosthetic salvage patients received intravenous antibiotics followed by surgical débridement, insertion of polymethylmethacrylate plates, device exchange, and postoperative antibiotics. After clinical resolution of infection, tissue expansion was performed, with the polymethylmethacrylate plates remaining in situ until exchanged for permanent implants.
The authors' study demonstrated a primary infection clearance rate of 82.2 percent (n = 37). Compared to the traditional explantation group, a significantly higher percentage of the salvage patients completed final reconstruction (84.4 percent versus 35.3 percent; p < 0.001). Fewer patients abandoned reconstruction efforts after infection clearance (2.2 percent versus 58.8 percent; p < 0.001). The majority of cases (78.8 percent) that succeeded the salvage protocol ultimately received implant-based reconstruction; 62.5 percent that failed the salvage protocol still went on to receive autologous tissue reconstruction.
Sustained local antibiotic delivery using polymethylmethacrylate implants and expander device exchange can successfully salvage an infected breast expander/implant. Compared with the traditional explantation approach, more patients complete final reconstruction. Other benefits include preserved skin envelope integrity and possibly improved long-term aesthetic outcomes.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
在乳房重建中,假体周围感染是一种主要的并发症,常常导致扩张器-植入物的丢失。目前对于尝试挽救的管理方案尚无共识。本研究评估了作者使用载抗生素聚甲基丙烯酸甲酯植入物和扩张器装置交换的挽救方案的结果。
回顾性图表回顾确定了 2009 年至 2017 年间治疗的感染性假体乳房重建病例。在最初确定的 626 例中,共有 62 例假体严重感染,其中 45 例接受假体挽救(n = 45),17 例接受立即取出(n = 17)。所有假体挽救患者均接受静脉内抗生素治疗,随后进行清创术、聚甲基丙烯酸甲酯板插入、装置交换和术后抗生素治疗。在感染临床治愈后,进行组织扩张,聚甲基丙烯酸甲酯板保持原位,直到更换为永久性植入物。
作者的研究表明,原发性感染清除率为 82.2%(n = 37)。与传统的取出组相比,挽救组完成最终重建的患者比例明显更高(84.4%比 35.3%;p < 0.001)。感染清除后放弃重建努力的患者比例较低(2.2%比 58.8%;p < 0.001)。大多数病例(78.8%)通过挽救方案成功接受了基于植入物的重建;62.5%的挽救方案失败的病例仍接受了自体组织重建。
使用聚甲基丙烯酸甲酯植入物和扩张器装置交换持续局部给予抗生素可以成功挽救感染的乳房扩张器/植入物。与传统的取出方法相比,更多的患者完成最终重建。其他好处包括保持皮肤包膜的完整性,并且可能改善长期美观效果。
临床问题/证据水平:治疗,III 级。